Vetter continues to expand its activities in China

Vetter's new sales branch emphasizes the importance of the Chinese market for the pharmaceutical service provider. Oskar Gold, Chervee Ho, and Jason Zhong (l. to r.) serve as the main contacts. (Image source: Vetter Pharma International GmbH)

- New office emphasizes the importance of the Chinese market for Vetter
- Local presence promotes new customer business
- Comprehensive service portfolio supports emerging Chinese companies in accessing the global market

Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has today opened its new branch in Shanghai. With its now fourth representation in the Asia-Pacific region (APAC), the pharmaceutical service provider aims to strengthen its international orientation and further increase its visibility in the strategically important Chinese market. Through the local presence, the company can now serve customers even better and build relationships with new clients more easily. The world's second-largest pharmaceutical market, with steady growth rates, also offers promising potential for injectable medicines. Vetter can support emerging Chinese companies in bringing their active ingredients to the global market. With its many years of experience, the pharmaceutical service provider supports everything from early process development through clinical and commercial filling to a variety of packaging solutions for vials, syringes, and cartridges.

“We are convinced that our renewed investment in the Asia-Pacific region will bear fruit quickly and support our further global growth,” said Vetter CEO Peter Sölkner. “The Asian share among the top 50 pharmaceutical companies worldwide has increased significantly in recent years. We also want to serve their needs as part of our global customer base as best as possible.” Oskar Gold, Senior Vice President Asia-Pacific/Emerging Global Markets, adds: “I am pleased that we can now further expand our international network from our new office in China in one of the most important markets in the APAC region.” The new branch is led by Jason Zhong, Business Development Manager China. He reports to Chervee Ho, Director Key Account Management Asia Pacific, based in Singapore.

The new office in Puxi, Shanghai, is centrally located in the heart of the Central Business District. It follows existing branches of the pharmaceutical service provider in the Asia-Pacific region in Singapore, Japan, and South Korea.